We have launched 4 self-developed monoclonal antibody (mAb) biosimilars including the first Chinese biosimilar 汉利康® (rituximab), the first Chinese mAb biosimilar entering both China and the EU market 汉曲优® (trastuzumab) and , 汉达远® (adalimumab), and 汉贝泰® (bevacizumab), navigating at the forefront of Chinese biopharmaceutical industry.
Adopting "Combo+Global" differentiation strategy, we have versatile in-house combination therapy portfolio with Serplulimab (anti-PD-1 mAb) as backbone. Multiple clinical trials are underway (including 2 international multi-centre clinical trials).
Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies.
We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 24,000L for now with an estimate of 48,000L within 2022 and 144,000L in 2025. Xuhui Facility is certificated by China and the EU Good Manufacturing Practice (GMP). Songjiang First Plant is certificated by China GMP.
We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 450 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
Henlius upholds the talent philosophy of "attracting people with visions, engaging people with rewards, cultivating people with challenges and assessing people with performance" and makes great efforts in attracting, empowering, retaining people and putting right people to right place.